Topic Highlight Open Access
Copyright ©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jun 14, 2006; 12(22): 3481-3486
Published online Jun 14, 2006. doi: 10.3748/wjg.v12.i22.3481
Bioinformatic approach for understanding the heterogeneity of cholangiocytes
Koji Fukushima, Yoshiyuki Ueno, Division of Gastroenterology, Tohoku University Graduate School of Medicine, Seiryo, Aobaku, Sendai, 980-8574, Japan
Author contributions: All authors contributed equally to the work.
Supported by Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan for the Research on Measures for Intractable Diseases and GRANT-IN-AID FOR SCIENTIFIC RESEARCH C (16590573) from JSPS
Correspondence to: Yoshiyuki Ueno, MD, PhD, Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1Seiryo, Aobaku, Sendai, 980-8574, Japan. yueno@mail.tains.tohoku.ac.jp
Telephone: +81-22-7177171 Fax: +81-22-7177177
Received: January 18, 2006
Revised: February 10, 2006
Accepted: February 18, 2006
Published online: June 14, 2006

Abstract

It is remarkable that microarray technologies have nearly reached a pinnacle. Establishment of further analysis and management of enormous data derived from microarray technology is currently the highest priority. The heterogeneous functions of cholangiocytes regulate the pathophysiology of the biliary epithelium in relation to secretory, proliferative and apoptotic activities. Distinct expression profiles of two murine cholangiocyte lines, termed small and large have been revealed by microarray analysis. The features of the two cholangiocyte cell lines, categorized partly according to gene ontology, indicate the specific physiological role of each cell line. The large cholangiocytes are characterized as “transport” and “immune/ inflammatory responses”. In contrast, small cholangiocytes are associated with properties of limited physiological functional ability and proliferating/migrating potential with specific molecules like Eph receptors, comparable to mesenchymal cells. 'Omic study will be of great help in understanding the heterogeneity of cholangiocytes.

Key Words: Cholangiocytes; Heterogeneity



INTRODUCTION

Several research avenues have established novel scientific theories. We initially examined phenotypic manifestations of various forms of induction, analogy and abduction. Subsequent preliminary studies resulted in a firm-working hypothesis. We then tested this hypothesis in order to establish our theoretical groundwork. However, recent advances in the field of bioinformatics have become routine, especially in regards to the initial speculative step in designing a rational approach. Since the initial DNA microarray analysis experiment[1], microarray has developed rapidly and is now well established, with manufacturers meeting market demand[2]. The number of scientific papers with "microarray" as a key word steadily increased on PubMed from 2001 to 2004, reaching a total of 8603 papers. Moreover, an enormous quantity of raw data potentially contained in "microarray" papers is anticipated in the near future, and the estimate is based on the number of the genes analyzed in each paper (e.g. 30 000-40 000 genes expressed in mammalian cells). Therefore, it is essential for future advances to reliably preserve a database containing all the raw data. The establishment of data analysis system as well as data mining and data sharing, is anticipated to be the highest priority in this field. We will focus on such issues pertaining to general microarray experiments as well as the methods and the results of microarray analyses designed to characterize cholangiocytes in this chapter.

MICROARRAY ANALYSIS

We will simply give an overview of the current status, analytic method and data-sharing aspects of microarray analysis, partly in accordance with the description of Knudsen[3]. One of the currently popular microarray systems is the Affymetrix DNA Chip®, which employs in situ oligonucleotide synthetic technology as well as mass-production compatible to that of silicon chips. Several microarrays and expression analysis services are commercially available from several companies including Amersham, Clontech (TAKARA), Invitrogen and so on. As in other experiments, the quantity of RNA samples should be standardized, otherwise correction steps will be necessary for the evaluation of the results by "scaling" generally employing internal controls. Moreover, verification of the linearity of spot intensity-sample quantity curves for all applied spots is also necessary in microarray experiments. The companies supplying ready-made products have overcome these problems and established quality control, making their products popular with researchers applying commercial products to limited numbers of samples. Although array technologies at the bench have nearly reached a zenith during the past several years, there are some in silico systems under development. The parametric t-test and non-parametric Wilcoxon's rank-sum/ Mann-Whitney tests are the most popular methods applicable to test the significance of differences between pairs of samples. The normality of each spot intensity for the samples becomes an issue if the t-test or ANOVA is used with a routine microarray having thousands of spots. The most conservative statistical method, Bonferroni's correction, which defines the level of significance more strictly according to the number of tested items, might be applicable even to microarray experiments[4]. Even if we employ other less conservative approaches[5], we may need to verify the differential expressions of the specific molecules by other methods in some cases. Several software programs are available, including some that are free like Cluster (http://rana.lbl.gov/EisenSoftware.htm)[6], for analysis of microarray data. Cluster analysis categorizes each gene into distinct clusters according to Euclidian distance based on the variation among the samples at multiple time-points or under the different conditions. Each gene in a cluster shows a similar expression pattern under different conditions, which may indicate a common transcription pathway, RNA degradation process, and/ or similarities of gene function in a cluster. In other words, microarray technology holds promise for elucidating the complex regulatory mechanisms of RNA transcription as well as unknown gene functions. Every gene is currently being systematically defined, allowing organization according to gene ontology (http://www.geneontology.org/). The gene ontology project was originally designed to create a thesaurus-like hierarchy of gene properties, based on molecular function, biological processes and cellular components, in order to integrate databases in a unified way. The combination of raw microarray data and this unified classification will greatly facilitate developing the speculative groundwork for our experiments. This approach differs from the usual methodology based on molecular properties including domain structure, 3D structure, evolution or expression patterns. Therefore, raw microarray data can be a source of new hypotheses, regardless of the original aim of the experiment. This may make it difficult to share raw microarray data. The unified approach, termed MIAME (http://www.mged.org/Workgroups/MIAME/miame.html), for submission of microarray data is described in the guidelines of each paper contributing data to be shared and for peer review. The statement that "MIAME is neither a dogma, nor a legal document-it assumes a cooperative data provider and a fair reviewer" suggests potential difficulty in data sharing, probably stemming from the complexities of ownership and intellectual property rights to data. Microarray data is clearly precious, even in the current era of non-sharing, and should be carefully stored by each lab, organization or government. Such data should be viewed as common property, with potential future benefits to mankind.

FEATURES OF CHOLANGIOCYTES

Bile flows from canalicular spaces, encircled by hepatocytes, through the canals of Hering, interlobular bile ducts (branches of which are 20-100 μm in diameter and lined by cuboidal epithelium), and septal bile ducts (which are more than 100 μm in diameter and lined by a simple tall columnar epithelium) to hilar intrahepatic bile ducts[7]. The cholangiocytes that line the interlobular and bolder bile ducts[7] also contribute to bile secretion[8,9]. The mechanism underlying this phenomenon, described elsewhere in detail, is explained briefly by out-intraluminal vectorial passive transport of water caused by the osmotic gradient which is formed by active transport of several substrates driven by cholangiocytes[10,11]. This physiological function, conserved even in cultured cell lines, characterizes the specialized cholangiocytes. Isolated rat cholangiocytes are classified as large or small, depending on their size. Large cholangiocytes, regarded as representative functional biliary epithelial cells in vivo, respond to secretin with increased choleresis[12]. In contrast, little is known about the properties of small cholangiocytes. Cholangiocytes are sometimes altered in a disease-specific manner. For example, primary biliary cirrhosis (PBC), a potentially fatal cholestatic disorder due to ductopenia, is a representative disease characterized by specific destruction of interlobular bile ducts. CD8+ cytotoxic T cells are suspected to play a major role in this type of destruction. Tetramer technology reveals the existence of an E2 subunit of the pyruvate dehydrogenase complex (PDC-E2)159-167-specific to autoreactive cytotoxic T cells in PBC[13]. Hypothetically, there are several specific properties (e.g. adhesion molecules, MHC antigens[14], specific autoantigens, variations in apoptosis and so on) of cholangiocytes lining interlobular bile ducts, which make them vulnerable to attack by cytotoxic lymphocytes. A novel disease etiology was proposed by Gershwin et al[15], who demonstrated that IgA class anti-mitochondrial antibodies, transported via transcytosis from the basolateral to the apical surface co-localize with PDC-E2 in cholangiocytes. Moreover, molecules that bind PDC-E2 monoclonal antibody are expressed on the apical membranes of PBC cholangiocytes[15]. These observations indicate the cytotoxicity associated with functional impairment of cholangiocytes to be caused by interaction with IgA-PDC-E2. In this regard, the mechanism of transcytosis may specifically dictate the underlying disease process. Such a hypothesis could be explained by cholangiocyte heterogeneity based on the recognition that large and small cholangiocytes are derived from bile ducts of corresponding diameters[16]. The susceptibility of bile ducts to pathological conditions (e.g. chronic ductopenic rejection[17], GVHD[18], ischemic cholangitis[19], PBC or ductopenia resulting from other pathologies) is due not only to the specific destruction of cholangiocytes, but also to the difficulty in regeneration of the bile ducts i.e. with normal structures, in contrast to the rapid regeneration of hepatocytes in cases with acute liver injury. The proliferation of cholangiocytes that potentiate the regeneration of bile ducts occurs in a characteristic manner, i.e. secretin, somatostatin or bile duct ligation results in proliferation of large cholangiocytes[20], whereas chemical injury of bile ducts with CCl4 increases the numbers of small cholangiocytes[21,22]. Therefore, to clarify the mechanisms sustaining cholangiocyte growth it is essential to understand the regulation of bile duct regeneration. We identified an Eph receptor, a membrane bound-type tyrosine kinase, as one of the key molecules for reorganization/proliferation of cholangiocytes, and a subtype of this family, which is expressed mainly in small cholangiocytes[23]. Thus, the heterogeneous expression profile of cholangiocytes is expected to facilitate further study of these cells.

ANALYSIS OF HETEROGENEOUS CHOLAN-GIOCYTES

For the evaluation of genes that are expressed by small and large cholangiocytes see Table 1. Several liver diseases, including non-alcoholic fatty liver disease[24], liver cirrhosis[25], hepatocellular carcinoma[26,27] and cholangiocellular carcinoma[28] have been studied extensively using microarray techniques. Some studies have examined whole liver samples, consisting of various cell types, probably for the purpose of disease classification. Sample size is critical for the detection of subtle changes in the expression of meaningful genes[29], a possible problem in assessing rare diseases. Another problem in the study of biliary diseases like PBC by microarray is that cholangiocytes account for only 3% of the cell population even in the normal liver[30]. Over 75% of the cell population is regarded as necessary to test the significance of differences in expression levels[2]. Therefore, for the purpose of analyzing chlangiocytes, isolation[31] or microdissection[32] is necessary prior to analysis. Our study goals were to characterize the physiological role of biliary epithelia in the mouse and to analyze cholangiocyte heterogeneity. Due to the complexities of the isolation steps, maintaining quality control or reproducibility was possible when obtaining a large sample of RNA from freshly isolated cholangiocytes. Moreover, given the necessity of conducting further functional assays, we immortalized and subcloned the isolated Balb-c mouse cholangiocytes by introducing the SV40 large T antigen[33]. The established large and small cholangiocyte cell lines were evaluated by their morphologies and responsiveness to secretin. We revealed 230 genes (4.74%) showing different expression patterns in the two cells lines, among 4800 genes tested by combining two types of ready-made microarrays[34]. Our large cholangiocyte line was characterized by gene ontology, transport and immune/inflammatory responses, which were apparent, even without the statistical tests presented in the table. The term "transport" includes movement of anions, water and bile acids, and thus represents the physiological functions of bile ducts. These observations indicate a special feature of large cholangiocytes which presumably play a role in local immune reactions. In contrast, our small cholangiocytes are categorized into a subgroup characterized by rapid cell cycle turnover as well as poor physiological functional ability. In addition to these fundamental properties, our small cholangiocytes are characterized by abundant expressions of actin and vimentin and poor expression of E-cadherin. Together with rich spindle-type cell processes, small cholangiocytes have a feature in common with mesenchymal cells probably originating from epithelial-mesenchymal transition[35]. This remains a controversial issue. Another important feature of cholangiocyte is its capability of the responsiveness to hormones and neuropeptides. Specifically, estrogen receptor[36] and receptor for IGF-1(insulin like growth factor 1)[37], NGF(nerve growth factor)[38] and acetylcholine (M3)[39] have been shown to play a major role in modulating cholangiocyte proliferation. Estrogen receptor expresses at a minimal level in both types of cell lines. In contrast, IGF receptor was preferentially expressed in large cholangiocyte line in our microarray study. The expression of estrogen receptor inducible under pathological conditions like bile duct injury[40] may explain the discrepancy between the experiments results. Predominant expression of IGF receptor in large cholangiocytes may be a marker of differentiated biliary epithelial cells as well as a proliferating effector of maturated cholangiocytes.

Table 1 Differences in cDNA expression between small and large cholangiocyte lines.
GO1 annotation/ Gene nameGene accessionGO accessionSmall2Large3Ratio (L/S)
Immune responseGO:0006955
CD1d1 antigenNM_0076391071561.46
CD1d2 antigenNM_007640801311.64
CD86 antigen; B7-2; CD28 antigen ligand 2 (CD28L2)L2560652170.33
Histocompatibility 2, class II antigen E alphaNM_0103811324073.08
Histocompatibility 2, class II antigen A, beta 1NM_0103795868321.42
Histocompatibility 2, class II antigen E betaNM_010382357944811.25
Interleukin 2 receptor, beta chainNM_00836854026044.83
Cell adhesionGO:0007155
Intercellular adhesion molecule 1 (ICAM1)X5226439200.51
Vascular cell adhesion molecule 1 (VCAM1)M8448717110.65
Cadherin 1 (CDH1); epithelial cadherin (E-cadherin; E-CAD); uvomorulin (UM)X0611532421.29
CytoskeletonGO:0005856
Cytoplasmic beta-actin (ACTB)M124814552750.60
Vimentin (VIM)X51438260730.28
ProteolysisGO:0006508
Matrix metalloproteinase 14 (MMP14); membrane-type matrix matalloproteinase 1 (MTMMP1)X83536258513390.52
Cell deathGO:0008219
Fas antigen ligand (FASL); apoptosis antigen ligand (APTL; APT1LG1); tumor necrosis factor superfamily member 6 (TNFSF6); generalized lymphoproliferative disease protein (GLD)U0694837210.57
Fas antigen; fasL receptor; apoptosis antigen 1 (APO1; APT1); CD95 antigenM8364918201.07
Fas death domain-associated proteinNM_0078293921030.26
Fas-associating protein with death domainNM_0101754841880.39
B-cell leukemia/lymphoma protein 2 (BCL2)M1650631180.56
Caspase 9NM_0157333189963.14
Anti-apoptosis
Insulin-like growth factor 1 receptor alpha subunit (IGFIR-alpha)U00182GO:0006916951761.86
Inflammatory responseGO:0006954
Tumor necrosis factorNM_0136931302752.11
Tumor necrosis factor (ligand) superfamily, member 4NM_009452982272.32
Tumor necrosis factor (ligand) superfamily, member 7NM_0116171332391.80
Tumor necrosis factor (ligand) superfamily, member 8NM_0094031895142.73
Tumor necrosis factor (ligand) superfamily, member 9NM_0094042783051.10
Tumor necrosis factor (ligand) superfamily, member 19NM_011615164880.53
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A); tumor necrosis factor receptor 1 (TNFR1)X5779658410.72
Tumor necrosis factor receptor superfamily member 1B2 (TNFRSF1B2); tumor necrosis factor receptor 2 (TNFR2)M5937818170.92
Interleukin 6 receptor alpha subunit (IL6R-alpha; IL6RA)X5197557641.13
Cytokine activityGO:0005125
Interleukin 6 (IL6)X0620336250.70
Oncostatin M (OSM)D31942795096.42
Cellular metabolismGO:0044237
PDC-E2NTNT
PDC-E3BPNTNT
TransportGO:0006810
Solute carrier family 4 (anion exchanger), member 2NM_009207801451.82
Solute carrier family 4 (anion exchanger), member 3NM_009208521202.31
Solute carrier family 4 (anion exchanger), member 1NM_01140399521462.16
Voltage-dependent anion channel 1NM_0116941111461.32
Voltage-dependent anion channel 2NM_01169587620.71
Solute carrier family (organic anion transporter) member 1NM_013797761141.50
Aquaporin 1NM_0074722572450.95
Aquaporin 2NM_0096991982761.39
Aquaporin 3NM_0166891242041.64
Aquaporin 5NM_0097013962220.56
Aquaporin 8NM_0074742160 8728 4.04
Solute carrier family 10 (sodium/bile acid cotransporter family), member 1NM_0113872084021.93
G-protein coupled purinergic receptor P2Y1 (P2RY1)U228293466521.89
Purinergic receptor P2X, ligand-gated ion channel 4NM_01102671122293.13
Detection of StimulusGO0051606
Toll-like receptor 2NM_01190595680.72
Toll-like receptor 5NM_0169281681140.68
Toll-like receptor 6NM_0116042555692.23
Cell proliferationGO:0008283
FMS-like tyrosine kinase 1 (FLT1); vascular endothelial growth factor receptor 1 (VEGFR1)L0729736230.65
Epidermal growth factor (EGF)J00380881161.32
Kinase insert domain receptor (KDR); vascular endothelial growth factor receptor 2 (VEGFR2); FLK1X7084293580.62
Vascular endothelial growth factor (VEGF); vascular permeability factor (VPF)M952001651520.92
Heparin-binding growth factor 5 (HBGF5); fibroblast growth factor 5 (FGF5)M306433551520.43
Fibroblast growth factor receptor 3 (FGFR3); heparin-binding growth factor receptor (HBGFR)M813421924852.53
Transforming growth factor beta 1 (TGF-beta 1; TGFB1)M13177691051.51
Transforming growth factor beta receptor 1 (TGF-beta receptor 1; TGFR1); ESK2D2554044290.65
Acetylcholine receptor M3NM_033269NTNT
Cell cycleGO:0007049
Proliferating cell nuclear antigen (PCNA); cyclinX530682111240.59
Cell growth
Estrogen receptor 1 (ESTR1); estrogen receptor alpha (ER-alpha; ESTRA)M38651GO:001604922331.48
Others
Nerve growth factor receptorAF105292GO:0007411N.T.N.T.
Neurotrophic tyrosine kinase receptor type1XM283871GO:0042490N.T.N.T.
Neurotrophic tyrosine kinase receptor type 2M33385GO:004249093180.20
Neurotrophic tyrosine kinase, receptor, type 3NM_008746GO:0042490292338271.31
Interferon gamma receptor (IFN-gamma receptor; IFNGR)M28233GO:000561551500.98
CONCLUDING REMARKS

Microarray is a powerful tool for elucidating functional cholangiocyte heterogeneity. Although the evaluation of some crucial biological regulatory processes like protein modification requires methodologies other than microarray, the potential of microarray technology is anticipated to grow with the development of data-analysis theory for the comprehension of complex networks.

ACKNOWLEDGMENTS

We thank Hiroyuki Izu (Center for Functional Analysis of DNA, TAKARA BIO Inc.) for his technical advice on the microarray.

Footnotes

S- Editor Wang J E- Editor Liu WF

References
1.  Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467-470.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6477]  [Cited by in F6Publishing: 5062]  [Article Influence: 174.6]  [Reference Citation Analysis (0)]
2.  Imbeaud S, Auffray C. 'The 39 steps' in gene expression profiling: critical issues and proposed best practices for microarray experiments. Drug Discov Today. 2005;10:1175-1182.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 49]  [Cited by in F6Publishing: 36]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
3.  Knudsen S ANALYSIS of DNA MICROARRAY DATA. New York: John Wiley & Sons Inc 2002; .  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Bender R, Lange S. Adjusting for multiple testing--when and how. J Clin Epidemiol. 2001;54:343-349.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1752]  [Cited by in F6Publishing: 1910]  [Article Influence: 83.0]  [Reference Citation Analysis (0)]
5.  Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100:9440-9445.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7208]  [Cited by in F6Publishing: 7072]  [Article Influence: 336.8]  [Reference Citation Analysis (0)]
6.  Li X, Rao S, Wang Y, Gong B. Gene mining: a novel and powerful ensemble decision approach to hunting for disease genes using microarray expression profiling. Nucleic Acids Res. 2004;32:2685-2694.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 80]  [Cited by in F6Publishing: 82]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
7.  Sherlock S Diseases of the Liver and Biliary System. 11th ed. Malden: Blackwell Science Inc 2002; .  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Nathanson MH, Boyer JL. Mechanisms and regulation of bile secretion. Hepatology. 1991;14:551-566.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 302]  [Cited by in F6Publishing: 259]  [Article Influence: 7.8]  [Reference Citation Analysis (0)]
9.  Alpini G, Lenzi R, Zhai WR, Slott PA, Liu MH, Sarkozi L, Tavoloni N. Bile secretory function of intrahepatic biliary epithelium in the rat. Am J Physiol. 1989;257:G124-G133.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Gong AY, Masyuk AI, Splinter PL, Huebert RC, Tietz PS, LaRusso NF. Channel-mediated water movement across enclosed or perfused mouse intrahepatic bile duct units. Am J Physiol Cell Physiol. 2002;283:C338-C346.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 35]  [Cited by in F6Publishing: 35]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
11.  Splinter PL, Masyuk AI, LaRusso NF. Specific inhibition of AQP1 water channels in isolated rat intrahepatic bile duct units by small interfering RNAs. J Biol Chem. 2003;278:6268-6274.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 51]  [Cited by in F6Publishing: 52]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
12.  Alpini G, Ulrich C, Roberts S, Phillips JO, Ueno Y, Podila PV, Colegio O, LeSage GD, Miller LJ, LaRusso NF. Molecular and functional heterogeneity of cholangiocytes from rat liver after bile duct ligation. Am J Physiol. 1997;272:G289-G297.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Kita H, Matsumura S, He XS, Ansari AA, Lian ZX, Van de Water J, Coppel RL, Kaplan MM, Gershwin ME. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest. 2002;109:1231-1240.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Hreha G, Jefferson DM, Yu CH, Grubman SA, Alsabeh R, Geller SA, Vierling JM. Immortalized intrahepatic mouse biliary epithelial cells: immunologic characterization and immunogenicity. Hepatology. 1999;30:358-371.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 20]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
15.  Gershwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ, Coppel RL. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev. 2000;174:210-225.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 199]  [Cited by in F6Publishing: 204]  [Article Influence: 8.5]  [Reference Citation Analysis (0)]
16.  Alpini G, Roberts S, Kuntz SM, Ueno Y, Gubba S, Podila PV, LeSage G, LaRusso NF. Morphological, molecular, and functional heterogeneity of cholangiocytes from normal rat liver. Gastroenterology. 1996;110:1636-1643.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 184]  [Cited by in F6Publishing: 179]  [Article Influence: 6.4]  [Reference Citation Analysis (0)]
17.  Wiesner RH, Ludwig J, van Hoek B, Krom RA. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology. 1991;14:721-729.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 128]  [Cited by in F6Publishing: 104]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
18.  Ueno Y, Ishii M, Yahagi K, Mano Y, Kisara N, Nakamura N, Shimosegawa T, Toyota T, Nagata S. Fas-mediated cholangiopathy in the murine model of graft versus host disease. Hepatology. 2000;31:966-974.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 51]  [Cited by in F6Publishing: 51]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
19.  Ludwig J, Batts KP, MacCarty RL. Ischemic cholangitis in hepatic allografts. Mayo Clin Proc. 1992;67:519-526.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 86]  [Cited by in F6Publishing: 81]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
20.  Alpini G, Glaser SS, Rodgers R, Phinizy JL, Robertson WE, Lasater J, Caligiuri A, Tretjak Z, LeSage GD. Functional expression of the apical Na+-dependent bile acid transporter in large but not small rat cholangiocytes. Gastroenterology. 1997;113:1734-1740.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 133]  [Cited by in F6Publishing: 138]  [Article Influence: 5.1]  [Reference Citation Analysis (0)]
21.  LeSage GD, Glaser SS, Marucci L, Benedetti A, Phinizy JL, Rodgers R, Caligiuri A, Papa E, Tretjak Z, Jezequel AM. Acute carbon tetrachloride feeding induces damage of large but not small cholangiocytes from BDL rat liver. Am J Physiol. 1999;276:G1289-G1301.  [PubMed]  [DOI]  [Cited in This Article: ]
22.  LeSage GD, Benedetti A, Glaser S, Marucci L, Tretjak Z, Caligiuri A, Rodgers R, Phinizy JL, Baiocchi L, Francis H. Acute carbon tetrachloride feeding selectively damages large, but not small, cholangiocytes from normal rat liver. Hepatology. 1999;29:307-319.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 85]  [Cited by in F6Publishing: 91]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
23.  Fukushima K UY, Kanno N, Moritoki Y, Inoue J, Shimosegawa T. Susceptible role and distinct distribution of Eph members in cholangiocyte. Gastroenterology. 2004;126:A750-750.  [PubMed]  [DOI]  [Cited in This Article: ]
24.  Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005;42:665-674.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 165]  [Cited by in F6Publishing: 155]  [Article Influence: 8.2]  [Reference Citation Analysis (0)]
25.  Kim S, Park YM. Specific gene expression patterns in liver cirrhosis. Biochem Biophys Res Commun. 2005;334:681-688.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 7]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
26.  Budhu AS, Zipser B, Forgues M, Ye QH, Sun Z, Wang XW. The molecular signature of metastases of human hepatocellular carcinoma. Oncology. 2005;69 Suppl 1:23-27.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 33]  [Cited by in F6Publishing: 36]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
27.  Mao HJ, Li HN, Zhou XM, Zhao JL, Wan DF. Monitoring microarray-based gene expression profile changes in hepatocellular carcinoma. World J Gastroenterol. 2005;11:2811-2816.  [PubMed]  [DOI]  [Cited in This Article: ]
28.  Obama K, Ura K, Li M, Katagiri T, Tsunoda T, Nomura A, Satoh S, Nakamura Y, Furukawa Y. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology. 2005;41:1339-1348.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 106]  [Cited by in F6Publishing: 105]  [Article Influence: 5.5]  [Reference Citation Analysis (0)]
29.  Wei C, Li J, Bumgarner RE. Sample size for detecting differentially expressed genes in microarray experiments. BMC Genomics. 2004;5:87.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 100]  [Cited by in F6Publishing: 103]  [Article Influence: 5.2]  [Reference Citation Analysis (0)]
30.  Alpini G, McGill JM, Larusso NF. The pathobiology of biliary epithelia. Hepatology. 2002;35:1256-1268.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 118]  [Cited by in F6Publishing: 125]  [Article Influence: 5.7]  [Reference Citation Analysis (0)]
31.  Ishii M, Vroman B, LaRusso NF. Isolation and morphologic characterization of bile duct epithelial cells from normal rat liver. Gastroenterology. 1989;97:1236-1247.  [PubMed]  [DOI]  [Cited in This Article: ]
32.  Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology. 2002;123:1090-1098.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 74]  [Cited by in F6Publishing: 61]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
33.  Yahagi K, Ishii M, Kobayashi K, Ueno Y, Mano Y, Niitsuma H, Igarashi T, Toyota T. Primary culture of cholangiocytes from normal mouse liver. In Vitro Cell Dev Biol Anim. 1998;34:512-514.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 27]  [Cited by in F6Publishing: 26]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
34.  Ueno Y, Alpini G, Yahagi K, Kanno N, Moritoki Y, Fukushima K, Glaser S, LeSage G, Shimosegawa T. Evaluation of differential gene expression by microarray analysis in small and large cholangiocytes isolated from normal mice. Liver Int. 2003;23:449-459.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 92]  [Cited by in F6Publishing: 87]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
35.  Boyer B, Vallés AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol. 2000;60:1091-1099.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 331]  [Cited by in F6Publishing: 351]  [Article Influence: 14.6]  [Reference Citation Analysis (0)]
36.  Alvaro D, Onori P, Metalli VD, Svegliati-Baroni G, Folli F, Franchitto A, Alpini G, Mancino MG, Attili AF, Gaudio E. Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. Hepatology. 2002;36:297-304.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 88]  [Cited by in F6Publishing: 89]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
37.  Alvaro D, Metalli VD, Alpini G, Onori P, Franchitto A, Barbaro B, Glaser SS, Francis H, Cantafora A, Blotta I. The intrahepatic biliary epithelium is a target of the growth hormone/insulin-like growth factor 1 axis. J Hepatol. 2005;43:875-883.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 60]  [Cited by in F6Publishing: 64]  [Article Influence: 3.4]  [Reference Citation Analysis (0)]
38.  Gigliozzi A, Alpini G, Baroni GS, Marucci L, Metalli VD, Glaser SS, Francis H, Mancino MG, Ueno Y, Barbaro B. Nerve growth factor modulates the proliferative capacity of the intrahepatic biliary epithelium in experimental cholestasis. Gastroenterology. 2004;127:1198-1209.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 69]  [Cited by in F6Publishing: 76]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
39.  LeSagE G, Alvaro D, Benedetti A, Glaser S, Marucci L, Baiocchi L, Eisel W, Caligiuri A, Phinizy JL, Rodgers R. Cholinergic system modulates growth, apoptosis, and secretion of cholangiocytes from bile duct-ligated rats. Gastroenterology. 1999;117:191-199.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 137]  [Cited by in F6Publishing: 140]  [Article Influence: 5.6]  [Reference Citation Analysis (0)]
40.  Alvaro D, Invernizzi P, Onori P, Franchitto A, De Santis A, Crosignani A, Sferra R, Ginanni-Corradini S, Mancino MG, Maggioni M. Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol. 2004;41:905-912.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 87]  [Cited by in F6Publishing: 91]  [Article Influence: 4.6]  [Reference Citation Analysis (0)]